Literature DB >> 28112182

Hippocampal CysLT1R knockdown or blockade represses LPS-induced depressive behaviors and neuroinflammatory response in mice.

Jing-Ran Lin1, Shun-Chang Fang1, Su-Su Tang1, Mei Hu1, Yan Long1, Arijit Ghosh1, Hong-Bin Sun1, Ling-Yi Kong1, Hao Hong1.   

Abstract

Evidence suggests that neuroinflammation is involved in depression and that the cysteinyl leukotriene receptor 1 (CysLT1R) plays a potential pathophysiological role in several types of CNS disorders. Our previous study has shown that knockdown of hippocampal CysLT1R in mice prevents the depressive-like phenotype and neuroinflammation induced by chronic mild stress (CMS). Here, we examined the effects of hippocampal CysLT1R knockdown and CysLT1R blockade on LPS-induced depressive-like behavior in mice. We found that injection of LPS (0.5 mg/kg, ip) caused marked increase in hippocampal CysLT1R expression, which was reversed by pretreatment with fluoxetine (20 mg·kg-1·d-1 for 7 d, ig). Knockdown of hippocampal CysLT1R or blockade of CysLT1R by pretreatment with pranlukast (0.5 mg/kg, ip) significantly suppressed LPS-induced depressive behaviors, as evidenced by decreases in mouse immobility time in the forced swimming test (FST) and tail suspension test (TST) and latency to feed in the novelty-suppressed feeding (NSF) test. Moreover, both CysLT1R knockdown and CysLT1R blockade markedly prevented LPS-induced neuroinflammation, as shown by the suppressed activation of microglia and NF-κB signaling as well as the hippocampal levels of TNF-α and IL-1β in mice. Our results suggest that CysLT1R may be involved in LPS-induced depressive-like behaviors and neuroinflammation, and that downregulation of CysLT1R could be a novel and potential therapeutic strategy for the treatment of depression, at least partially due to its role in neuroinflammation.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28112182      PMCID: PMC5386312          DOI: 10.1038/aps.2016.145

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  48 in total

Review 1.  Biological basis of the behavior of sick animals.

Authors:  B L Hart
Journal:  Neurosci Biobehav Rev       Date:  1988       Impact factor: 8.989

Review 2.  Depression: an inflammatory illness?

Authors:  Rajeev Krishnadas; Jonathan Cavanagh
Journal:  J Neurol Neurosurg Psychiatry       Date:  2012-03-15       Impact factor: 10.154

3.  Depressive-like behavior induced by tumor necrosis factor-α in mice.

Authors:  Manuella P Kaster; Vinícius M Gadotti; João B Calixto; Adair R S Santos; Ana Lúcia S Rodrigues
Journal:  Neuropharmacology       Date:  2011-08-18       Impact factor: 5.250

Review 4.  Cysteinyl leukotrienes and their receptors: molecular and functional characteristics.

Authors:  R K Singh; S Gupta; S Dastidar; A Ray
Journal:  Pharmacology       Date:  2010-06-02       Impact factor: 2.547

5.  Salvianolic acid B ameliorates depressive-like behaviors in chronic mild stress-treated mice: involvement of the neuroinflammatory pathway.

Authors:  Jin-Qiang Zhang; Xiao-Hui Wu; Yi Feng; Xiao-Fang Xie; Yong-Hua Fan; Shuo Yan; Qiu-Ying Zhao; Cheng Peng; Zi-Li You
Journal:  Acta Pharmacol Sin       Date:  2016-07-18       Impact factor: 6.150

6.  Rho kinase inhibitor fasudil protects against β-amyloid-induced hippocampal neurodegeneration in rats.

Authors:  Yun Song; Xu Chen; Li-Yan Wang; Wei Gao; Mei-Jia Zhu
Journal:  CNS Neurosci Ther       Date:  2013-05-03       Impact factor: 5.243

7.  Knockdown of hippocampal cysteinyl leukotriene receptor 1 prevents depressive behavior and neuroinflammation induced by chronic mild stress in mice.

Authors:  Xu-Ben Yu; Rong-Rong Dong; Hui Wang; Jing-Ran Lin; Yun-Qi An; Yong Du; Su-Su Tang; Mei Hu; Yan Long; Hong-Bin Sun; Ling-Yi Kong; Hao Hong
Journal:  Psychopharmacology (Berl)       Date:  2015-11-07       Impact factor: 4.530

8.  Minocycline attenuates lipopolysaccharide (LPS)-induced neuroinflammation, sickness behavior, and anhedonia.

Authors:  Christopher J Henry; Yan Huang; Angela Wynne; Mark Hanke; Justin Himler; Michael T Bailey; John F Sheridan; Jonathan P Godbout
Journal:  J Neuroinflammation       Date:  2008-05-13       Impact factor: 8.322

9.  Antidepressant effects of TrkB ligands on depression-like behavior and dendritic changes in mice after inflammation.

Authors:  Ji-chun Zhang; Jin Wu; Yuko Fujita; Wei Yao; Qian Ren; Chun Yang; Su-xia Li; Yukihiko Shirayama; Kenji Hashimoto
Journal:  Int J Neuropsychopharmacol       Date:  2014-10-31       Impact factor: 5.176

10.  Structural and functional rejuvenation of the aged brain by an approved anti-asthmatic drug.

Authors:  Julia Marschallinger; Iris Schäffner; Barbara Klein; Renate Gelfert; Francisco J Rivera; Sebastian Illes; Lukas Grassner; Maximilian Janssen; Peter Rotheneichner; Claudia Schmuckermair; Roland Coras; Marta Boccazzi; Mansoor Chishty; Florian B Lagler; Marija Renic; Hans-Christian Bauer; Nicolas Singewald; Ingmar Blümcke; Ulrich Bogdahn; Sebastien Couillard-Despres; D Chichung Lie; Maria P Abbracchio; Ludwig Aigner
Journal:  Nat Commun       Date:  2015-10-27       Impact factor: 14.919

View more
  3 in total

1.  Protective Effects of 1-Methylnicotinamide on Aβ1-42-Induced Cognitive Deficits, Neuroinflammation and Apoptosis in Mice.

Authors:  Lili Fu; Caihong Liu; Liang Chen; Yangge Lv; Guoliang Meng; Mei Hu; Yan Long; Hao Hong; Susu Tang
Journal:  J Neuroimmune Pharmacol       Date:  2019-01-11       Impact factor: 4.147

2.  Atorvastatin ameliorates depressive behaviors and neuroinflammatory in streptozotocin-induced diabetic mice.

Authors:  Zhang Hai-Na; Yu Xu-Ben; Tang Cong-Rong; Cao Yan-Cheng; Yang Fan; Xu Lei-Mei; Sun Ruo-Lan; Wang Ye-Xuan; Liang Jing
Journal:  Psychopharmacology (Berl)       Date:  2019-11-30       Impact factor: 4.530

3.  Hippocampal CA1 βCaMKII mediates neuroinflammatory responses via COX-2/PGE2 signaling pathways in depression.

Authors:  Qiqi Song; Cuiqin Fan; Peng Wang; Ye Li; Mu Yang; Shu Yan Yu
Journal:  J Neuroinflammation       Date:  2018-12-08       Impact factor: 8.322

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.